# Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer

> **NCT00004081** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00004081
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2002-01
- **Final completion:** 2003-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004081, "Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00004081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*